Established in 2015, Xgene Pharmaceutical Inc. engineers high-impact medications for unmet underserved needs in neurological conditions. Xgene’s proprietary linker technology generates novel dual-acting conjugates combining two well-characterized and efficacious therapeutic molecules to produce a targeted multimodal approach. The conjugated prodrug molecules exhibit different – modified by the linker – absorption, pharmacokinetic, and metabolic characteristics as compared to either parent drug. Preclinical studies of these conjugates demonstrate that the Xgene’s linker modification results in lower toxicity and superior efficacy in several conditions characterized by high unmet need.
Our vision is to develop superior products by leveraging clinical knowledge and basic research to achieve better treatment for patients.
Our mission is to bring more effective, safer products to market with efficient development process.
Xgene has completed 3 rounds of financing: Round A 2016 Q1; Round B 2018 Q4; Round C 2021 Q4.
For more information, contact Dr. Iwona Beczkowska, Exec. Director of Business Development, firstname.lastname@example.org